Copyright
©The Author(s) 2020.
World J Clin Cases. Aug 26, 2020; 8(16): 3390-3404
Published online Aug 26, 2020. doi: 10.12998/wjcc.v8.i16.3390
Published online Aug 26, 2020. doi: 10.12998/wjcc.v8.i16.3390
Ref. | n1 | Mean age | Outcomes | Results |
Liang et al[74], 2020 | 18 | 63 | Severe clinical events (ICU admission and mechanical ventilation or death) | Severe clinical events: 39% (7/18 patients) vs 8% (126/1572 patients without cancer) (P = 0.0003) |
Zhang et al[72], 2020 | 28 | 65 | Severe clinical events (ICU admission, life-threatening complications or death) | Severe clinical events: 53.6% (15/28 patients). Death rate: 28.6% (8/28 patients) |
Dai et al[75], 2020 | 105 | 64 | Death rate, ICU admission and severe or critical symptom | Death rate: 11.4% (OR 2.34, P = 0.03); ICU admission: 19.0% (OR 2.84, P < 0.01); Severe or critical symptom: 34.3% (OR 2.79, P < 0.01) |
Barlesi et al[79], 20202 | 137 | 61 | ICU admission or death | ICU admission: 11.0% (15/137 patients); Death rate: 14.6% (20/137patients) |
Yang et al[76], 2020 | 205 | 63 | ICU admission or death | ICU admission: 15.0% (30/205 patients); Death rate: 20.0% (40/205 patients) |
Kuderer et al[77], 2020 | 928 | 66 | ICU admission, mechanical ventilation or death | ICU admission: 14.2% (132/928 patients); Mechanical ventilation: 12.5% (116/928 patients); Death rate: 13.0% (121/928patients) |
Garassino et al[78], 20203 | 200 | 68 | ICU admission, mechanical ventilation in hospitalised patient and death in all patients | ICU admission: 8.8% (13/147 patients); Mechanical ventilation: 6.1% (9/147 patients); Death rate: 33.0% (66/200 patients) |
Priority | Clinical scenario | Examples |
High | Tumors with high early mortality associated and high response rate to treatment | Advanced germ cell tumors, lymphomas or acute leukemias |
Definitive curative cancer treatments | CRT for head and neck, cervical or anal cancers | |
Intermediate | Neoadjuvant or adjuvant therapies with high survival benefit | Perioperative ChT for gastric cancer and neoadjuvant CRT for localized rectal cancer. Adjuvant ChT for stage III or high risk stage II colorectal cancer, or stage III melanoma. ChT and RT for high risk breast cancer |
Neoadjuvant or adjuvant indications with modest survival benefit | Neoadjuvant ChT for muscle invasive bladder cancer. Adjuvant ChT for NSCLC, gallbladder and pancreatic cancer or gynecologic malignancies | |
Palliative indications with high survival benefit | Immunotherapy for melanoma, NSCLC (with PDL1 > 50%) or high risk kidney cancer. Systemic ChT for metastatic breast or colorectal cancer. Molecular targeted therapy for NSCLC with driver mutation. TKI for GIST or low risk kidney cancer, and ADT and abiraterone or docetaxel for castrate-sensitive prostate cancer | |
Low | Palliative indications with modest survival benefit | Palliative chemotherapy for upper gastrointestinal cancers. Chemotherapy for gallbladder or pancreatic cancer, SCLC or bladder cancer |
Palliative indications without benefits in terms of overall survival | Second and third line palliative ChT for many solid tumors, as regorafenib for colorectal cancer or ramucirumab and placlitaxel for gastric cancer |
- Citation: González-Montero J, Valenzuela G, Ahumada M, Barajas O, Villanueva L. Management of cancer patients during COVID-19 pandemic at developing countries. World J Clin Cases 2020; 8(16): 3390-3404
- URL: https://www.wjgnet.com/2307-8960/full/v8/i16/3390.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i16.3390